Teiko, a global CLIA-certified immune monitoring lab, today announced that Stingray Therapeutics has selected Teiko to provide mass cytometry-based multi-parameter immuneprofiling services in support of the clinical development of its leading novel innate immunecheckpoint inhibitor Vizenpistat (SR-8541A, ENPP1 inhibitor) targeting therapeutic program.
Teiko, a global CLIA-certified immune monitoring lab, today announced that Stingray Therapeutics has selected Teiko to provide mass cytometry-based multi-parameter immune profiling services in support of the clinical development of its leading novel innate immune checkpoint inhibitor Vizenpistat (SR-8541A, ENPP1 inhibitor).
Under the collaboration, Teiko will process and analyze cryopreserved peripheral blood mononuclear cell (PBMC) samples from patients enrolled in Stingray's ongoing clinical trial using its TokuFocus cytometry assay. All samples are acquired on Teiko's CLIA-validated 41-marker mass cytometry panel, and Stingray will initially receive focused T, B, NK, and myeloid (TBNKM) population results.
TokuFocus lowers the upfront cost of cytometry profiling while providing the key cell populations needed to monitor for early clinical responses. If interim results identify patients or cohorts that warrant deeper investigation, Stingray can unlock analysis of 840+ immune subsets from those same samples, paying only for what they need.
Results are delivered through Teiko's TokuProfile Dashboard, an AI-integrated platform that delivers analyzed cytometry data with cohort and endpoint comparisons, built-in statistics, and visualization tools, making it easy to interpret and share results.
ENPP1 is the only known checkpoint in innate immunity and a negative regulator of the cGAS-STING pathway. High levels of ENPP1 have been correlated with reduced immune infiltration, increased metastasis, and tumor resistance to both chemotherapy and adaptive immunotherapies. Teiko's immune profiling will allow Stingray to characterize the peripheral blood immune landscape in patients receiving treatment, helping to evaluate dose-response, better understand the therapy's mechanism of action, and identify immune cell populations that may be associated with clinical outcomes or patient response.
“We appreciate the ability to work with Teiko and use its TokuFocus system to develop Vizenpistat, our exciting first and best-in-class innate immune checkpoint inhibitor, a need in immune oncology we have been pursuing now for 10 years,” said Jon Northrup, Co-Founder and CEO of Stingray Therapeutics.
Stingray Therapeutics is a clinical-stage biotech company focused on developing next-generation immune therapies to combat cancer. Their revolutionary approach enables the full immune system to fight back against cancer, targeting the only known innate immunity checkpoint, ENPP1, to enhance immune response and reduce tumor resistance. Stingray Therapeutics is headquartered in Houston, TX, at the Texas Medical Center. For information, visit stingraytx.com.
Teiko is a global CLIA-certified cytometry lab for clinical trials. Teiko solves the problems translational scientists hate about flow cytometry on clinical trials: missing 20% of $1,000 blood specimens, lengthy panel builds, and bad gating. Teiko is working with groups like Genentech, Recursion, iOnctura, and dozens more to solve these problems. For more information, visit teiko-labs.com.
